Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
|Articles|September 20, 2012
Is Big Pharma getting too much Flak From Doctors?
Advertisement
Big Pharma's image problem, fueled by numerous high-profile scandals, may have made doctors so skeptical of the industry that it's warping their judgment, a new survey suggests.
Researchers found that doctors shown summaries of hypothetical drug tests lost their confidence in the results when a pharmaceutical company had paid for the studies.
Read the full story:
Source: Reuters
Advertisement
Related to this article
AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.
Birth centers are unavailable in 10 states, and 39% of birth center births are self-pay, as licensing and Medicaid pay limit access, a report finds.
Speakers at IDWeek 2026 urged shifting global health partnerships from donor-recipient models to shared, locally led ownership as funding contracts.
Off-the-shelf CTX110 allogeneic CD19 CAR T shows responses in relapsed/refractory B-cell lymphoma, with manageable cytokine release syndrome.
Nearly half of working-age adults were inadequately insured in 2026, and half went without needed care due to cost, a Commonwealth Fund survey found.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5